CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2015. “The second quarter was productive on multiple fronts for AVEO, including clinical updates, regulatory guidance and another partnership for tivozanib, in addition to completion of our corporate streamlining efforts,” said Michael Bailey, president and chief executive officer. “These accomplishments have positioned us well to continue pursuing several additi
| < Prev | Next > |
|---|
